Why is Kroger closing 60 stores?
How will Tesla's robotaxi launch affect stock?
What caused Meta's AI talent poaching spree?
Why did the Fed hold interest rates steady?
How is Israel-Iran conflict impacting oil prices?
Why are U.S. airlines suspending Middle East flights?
What does Circle's stock surge mean?
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
benzinga.com/news/health-care/25/06/46036263/capricor-reports-4-year-data-for-deramiocel-shows-sustained-benefit-in-duchenne-patients
Capricor Therapeutics (NASDAQ:CAPR) on Friday released four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD).
After four years of continuous treatment,…
This story appeared on benzinga.com, 2025-06-20 19:11:09.